Industries
Cancer Immunotherapy
Cancer immunotherapy harnesses the immune system to eliminate tumors, with checkpoint inhibitors, CAR-T cells, and cancer vaccines driving a transformation in oncology. Academic tumor immunology groups discover novel checkpoint targets, characterize immunosuppressive mechanisms, and develop neoantigen platforms that biotech companies license for clinical development.
Details
- Companies
- Bristol-Myers SquibbMerck OncologyAstraZeneca OncologyGenentech RocheRegeneron OncologyMerusInhibrxAgenusiTeos TherapeuticsALX Oncology
- Market Size
- $68B
- Target Researchers
- Tumor immunologists, cancer biologists, and translational researchers with expertise in checkpoint biology, tumor microenvironment, neoantigen prediction, T-cell dysfunction, and combination immunotherapy design
- Use Cases
- Neoantigen pipeline partnershipsNovel checkpoint target co-developmentTME biology research collaborationsCombination regimen biomarker studiesPredictive biomarker platform accessIO clinical pharmacology consulting